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Congenital heart defects (CHDs) are of public health concern because they affect 
approximately 1% of newborns,1-3 are a leading cause of infant mortality,4 and often result 
in increased use and costs of health services among affected children, adolescents, and 
adults.5 In recent decades, epidemiologic research has made notable progress in the 
identification of modifiable risk factors for some CHDs (eg, congenital rubella infection, use 
of certain medications, and pregestational diabetes).6 For most CHDs, however, the causes 
remain unknown. In this issue of The Journal, Sullivan et al7 describe results of a 
population-based study in which they assessed the possible association of maternal 
periconceptional cigarette smoking and the occurrence of CHDs among live births by 
linking self-reports of cigarette smoking on birth certificates with records of children with 
CHD (ie, cases) identified from birth certificates and a statewide hospital discharge registry. 
The authors examined 19 specific CHD phenotypes and observed associations between 
maternal cigarette smoking during the first trimester of pregnancy and 3 phenotypes: 
pulmonary valve anomalies, pulmonary artery anomalies, and isolated secundum type of 
atrial septal defects. They also observed a suggestion of a doseresponse relationship between 
maternal cigarette smoking and the risk of CHDs examined as a group. These findings are of 
interest because they highlight: (1) methodologic issues common to studies of associations 
of maternal cigarette smoking, a prevalent and modifiable exposure, with specific CHD 
phenotypes in the offspring; (2) challenges in interpreting the nature of observed 
associations between maternal cigarette smoking and CHDs; and (3) opportunities for 
prevention and smoking cessation efforts among women of childbearing age.
Methodologic Issues in Studies of Associations between Maternal Cigarette 
Smoking and CHD
There are a number of methodologic issues in epidemiologic studies of cigarette smoking 
and CHDs that careful design and execution can help address. CHDs encompass a wide 
range of phenotypes with varying severity and potentially different etiologies. These can 
involve a single cardiac lesion or multiple cooccurring cardiac lesions. Additional defects 
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also may be present in other organ systems. These additional defects may or may not be part 
of known genetic disorders. The different phenotypes of CHDs also can vary in risk factors 
and in the proportion that result in spontaneous fetal death or elective termination of 
pregnancy after prenatal diagnosis. The effect of inclusion or exclusion of these birth 
outcomes on the estimated prevalence may vary for different CHD phenotypes. Therefore, 
population-based studies of CHDs generally should aim to include all CHD cases among 
live births, stillbirths, and pregnancy terminations, whenever possible, to minimize the 
potential for selection bias and use a system of classification of CHD phenotypes into 
relatively homogeneous subgroups with respect to the presence of known underlying 
etiologies and the potential risk factors under study to maximize the potential for meaningful 
analysis.8
Classification of CHDs, however, into specific phenotypes requires expertise that often is 
not readily available, and, when available, can pose a dilemma for analysis. Although 
classification of specific CHD phenotypes may offer a better potential for identifying risk 
factors specific for such phenotypes, individual CHD phenotypes tend to be rare. The 
sample size obtained for a given phenotype in a given study may be inadequate for reliable 
analysis. A case-control study design often is used to examine multiple risk factors for 
various specific CHD phenotypes because this type of design generally is less costly and 
more efficient than cohort studies designed to examine one specific exposure in relation to 
the risk for various specific CHD phenotypes. However, case-control studies of prenatal 
exposures often rely on maternal self-reports (ie, subject to recall errors) that may result in 
misclassification of exposure status and possible biases in the relative risk estimates. 
Because of these and other methodologic issues (eg, accuracy of CHD phenotype 
classification based on International Classification of Diseases, 9th Revision, Clinical 
Modification codes, multiple comparisons of exposures and phenotypes), epidemiologic 
studies of cigarette smoking and CHDs clearly are challenging to conduct. Nonetheless, 
such studies are needed and valuable because they help to add to the body of literature on a 
possible risk factor for CHDs that is prevalent and potentially modifiable.6,9-11
Challenges in Interpreting the Causal Nature of the Association between 
Cigarette Smoking and CHDs
Interpreting associations between maternal cigarette smoking and CHDs is further 
complicated by the fact that different CHD phenotypes are multifactorial in origin, involving 
complex interplays between genetic and environmental factors, so that infants with the same 
CHD phenotype (eg, hypoplastic left heart syndrome) may exhibit different risk factor 
profiles. Therefore, in interpreting whether observed associations between one type of 
exposure such as cigarette smoking and specific CHDs are likely to be causal, it is useful to 
consider the quality of the evidence with respect to guidelines for establishing causality for a 
given exposure (ie, temporality, strength of association, biological or dose-response 
gradient, consistency across studies, plausibility/coherence, experimental evidence, and 
specificity).12 Maternal cigarette smoking can be considered causally related to oral clefts 
because there is moderate-to-strong evidence for 5 of the 7 guidelines for causality.9,13 In 
contrast, the evidence for causality for the association between maternal cigarette smoking 
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and right-sided obstructive heart lesions and secundum type of atrial septal defects is more 
limited: there is moderate-to-strong evidence for only 3 of the guidelines (temporality, 
strength of association, and specificity) and weak-to-moderate evidence for a fourth and fifth 
(consistency across studies and dose-response).9,11 However, there is little to no evidence 
for coherence/biologic plausibility and no experimental evidence in support of the 
associations between maternal cigarette smoking early in pregnancy and CHDs.
Thus, at present, the level of evidence regarding a causal relationship between maternal 
cigarette smoking and right obstructive heart defects and secundum atrial septal defects 
probably could be considered suggestive at best. Worth noting is that because most studies 
of CHDs and maternal cigarette smoking have involved multiple comparisons of various 
groupings of CHDs, there is always the concern that some of the observed associations in 
analyses of multiple exposures and/or phenotypes could reflect chance (ie, type I error). 
Further studies are needed to rule out chance and bias inherent to observational studies as 
possible explanations for the observed associations between maternal cigarette smoking and 
CHDs.9,11,14,15
In this issue of The Journal, Sullivan et al7 report on a population-based, case-control study 
in which they examined possible associations of CHDs with maternal cigarette smoking. 
They found frequencies of CHDs and of maternal cigarette smoking comparable with those 
reported in other recent population-based studies.14-16 In addition, they reported aORs for 
maternal cigarette smoking that were weakly to modestly associated with pulmonary valve 
anomalies (aOR 1.48, 95% CI 1.15-1.90); pulmonary artery anomalies (aOR 1.71, 95% CI 
1.40-2.09); and isolated secundum type of atrial septal defects (aOR 1.22, 95% CI 
1.08-1.38). These findings are consistent with findings from 2 population-based case-control 
studies that also examined maternal cigarette smoking and CHDs (Table).14,15 Furthermore, 
Sullivan et al7 reported a dose-response relationship between maternal cigarette smoking 
and the risk for all CHDs as a group, particularly among offspring of mothers 35 years of 
age and older. Because these dose-response data were presented only for all CHDs 
combined, and different studies differ in inclusion and exclusion criteria and classification 
systems for specific CHD phenotypes, direct comparison with previous studies is not 
possible.
Smoking Prevention and Cessation among Pregnant Women
Although the evidence for a causal relationship between cigarette smoking and CHDs is still 
open to question, the other known adverse effects of smoking for pregnancy outcomes9 and 
the current 10%-15% prevalence of smoking among women of childbearing age16 make it 
imperative to continue to support smoking prevention and cessation efforts in this 
population. A variety of measures could be adopted to prevent women from initiating 
smoking and to encourage those who currently smoke to quit. These include increasing the 
price of tobacco products, implementing and enforcing comprehensive smoke-free laws, and 
increasing access to help quitting.17-19 Increasing awareness of the consequences of 
smoking during pregnancy among women is also important. A recent study conducted 
among a sample of US women who smoke found that they were aware there were general 
health risks of smoking during pregnancy, such as an increase in premature delivery or 
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having an infant with low birth weight; however, many were not aware of other specific 
consequences, such as birth defects.20 Providing more information to women about the risks 
of smoking during pregnancy could motivate many of them to quit. Studies suggest that 
pregnant women are often motivated to change or adopt new behaviors because they want 
their unborn babies to be healthy.21,22 Health education efforts also could include 
antismoking media campaigns such as Centers for Disease Control and Prevention Tips from 
Former Smokers campaign,23 which features a story about the dangers of smoking during 
pregnancy.
Women who wish to quit smoking during pregnancy have options such as brief tobacco 
counseling (eg, the 5As: ask, advise, assess, assist, arrange24) in settings in which women of 
child-bearing age encounter medical professionals and calling a quitline. The ideal time to 
reach women with prevention messages and cessation assistance, however, is during the 
preconception period. By the time a woman finds out about her pregnancy and begins 
prenatal care, it may be too late to prevent some adverse outcomes, such as oral clefts, 
CHDs, and other birth defects, that occur early in pregnancy.25 Additionally, women who 
decide to quit smoking before pregnancy have more treatment options available for doing 
so. Cessation medication is not recommended as first-line treatment for pregnant women, 
and the safety and efficacy of nicotine-replacement therapy during pregnancy has not been 
established.10,26,27
The study by Sullivan et al7 adds to the body of literature on possible associations between 
maternal cigarette smoking early in pregnancy and 3 of 19 specific CHD phenotypes 
examined in the offspring. Although further studies are war-
ranted to corroborate the observed associations, the current evidence on adverse effects of 
maternal cigarette smoking on pregnancy outcomes suggests that the wisest course of action 
is to continue to promote smoking prevention and cessation efforts among women of 
childbearing age.
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Table
ORs from published studies of associations between maternal cigarette smoking, atrial septal defects, and right 



















infants OR (95% CI)
Malik, et al,15 US Atrial septal defects
‡ 69/458 2.02 (1.47-2.77) 22/190 1.78 (1.05-3.01) 6/45 2.35 (0.92-6.00)
Right ventricular outflow
 tract obstruction defects
79/522 1.25 (0.95-1.65) 23/204 0.93 (0.59-1.49) 13/47 2.35 (1.21-4.53)
Pulmonary valve stenosis 58/458 1.24 (0.90-1.70) 17/190 0.91 (0.53-1.55) 10/45 2.31 (1.11-4.83)
Alverson, et al,14 Atrial septal defects 






 tract obstruction defects
49/539 1.20 (0.88-1.69) 27/314 1.25 (0.81-1.91) 12/107 1.71 (0.92-3.18)
Pulmonary valve stenosis 45/539 1.53 (1.06-2.19) 18/314 1.15 (0.69-1.92) 9/107 1.79 (0.88-3.54)
Pulmonary atresia with
 intact ventricular septum
4/539 0.73 (0.25-2.14) 8/314 2.43 (1.06-5.53) 1/107 0.88 (0.12-6.62)
*
The study by Malik et al15 included maternal smoking from 1 month before conception through the end of the first trimester; smoking levels were 
defined as light, 1-14 cigarettes per day; medium, 15-24 cigarettes per day; heavy, ≥25 cigarettes per day.
†
The study by Alverson et al14 included maternal smoking during the first trimester; smoking levels were defined as light, 1-10 cigarettes per day; 
medium, 11-20 cigarettes per day; heavy, ≥21 cigarettes per day.
‡
This category refers to secundum type of atrial septal defects.
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